6505--PET Prostate-Specific Membrane Antigen Radiopharmaceuticals Amend for Questions and Answers

The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 is seeking to procure PET Prostate-Specific Membrane Antigen (PSMA) radiopharmaceuticals for prostate cancer diagnostic imaging. The solicitation encompasses multiple FDA-approved PSMA products, including fluciclovine F-18 (Axumin), gallium-68 PSMA-11 (Illuccix and Locametz), piflufolastat F-18 (Pylarify), and flotufolastat F-18 (Posluma). Key requirements include that the awarded contractor must assume full responsibility and accountability for providing contingency plans and alternative sources prior to award to ensure continuity of supply if local radio pharmacies cannot provide routine delivery, and must accommodate same-day afternoon delivery orders submitted before 10:00 AM (or another mutually agreed-upon cut-off time) to allow sufficient preparation and delivery logistics. This is a competitive Request for Quotation (RFQ) and not a sole-source procurement. The response deadline is January 26, 2026, at 5:00 PM Eastern Time, with the contracting officer being Stacy Massey at Stacy.Massey@va.gov.

No set-aside designation has been applied to this procurement, making it unrestricted and open to all qualified vendors. The solicitation specifies a base contract year running from February 1, 2026, to January 31, 2027, with pricing requested for 205 unit doses of F-18 PSMA imaging radiopharmaceutical at 9 mCi per dose, along with ancillary delivery and handling fees and an unused dose fee. The place of performance is the Jesse Brown VA Medical Center located at 820 South Damen Avenue in Chicago, Illinois. The procurement falls under NAICS code 325412 (Pharmaceutical Preparation Manufacturing) and Product Service Code 6505 (Drugs and Biologicals), with a small business size standard of 1,300 employees. The solicitation emphasizes the local production requirement of radioisotopes, reflecting the short shelf-life constraints inherent in PET pharmaceutical products.